Alkermes PLC is a biotechnology incorporated on May 4, 2011. The Company is engaged in developing, manufacturing and commercializing medicines to address unmet medical needs of patients in various therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders such as schizophrenia, depression, addiction and multiple sclerosis. The company is subject to the laws and regulations from the U.S. Foreign Corrupt Practices Act (FCPA).
Benzinga is a fast-growing, dynamic and innovative financial media outlet that empowers investors with high-quality, unique content.